好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Motor Dysfunction in Relapsing-Remitting Multiple Sclerosis: Association with Structural Brain Damage and Cognitive Impairment
Multiple Sclerosis
P1 - Poster Session 1 (9:00 AM-5:00 PM)
306

We assessed the contribution of cognitive dysfunction to motor impairment beyond structural disease-related burden in patients with multiple sclerosis (MS).

Previous studies demonstrated an association between motor and cognitive performance in MS, however the possible mediating role of structural brain damage remains unclear.

Eighty-one healthy controls and 109 relapsing-remitting (RR) MS patients underwent a 3.0T MRI with quantification of T2-lesion volumes (LV), T1-LV and normalized brain volumes; a functional examination (Nine-Hole Peg Test [9-HPT], Timed 25-Foot Walk test [T25FW], expanded disability status scale [EDSS]); RRMS also underwent neuropsychological evaluation. Association between demographic, clinical, cognitive, MRI and functional measures were analysed with univariate analyses and hierarchical linear regression. 
In RRMS, Spatial Recall Test and Symbol Digit Modalities Test were positively correlated with 9-HPT (p≤0.005) and T25FW (p≤0.049); Paced Auditory Serial Addition Test (PASAT) correlated with 9-HPT (p≤0.014). 9-HPT and T25FW were significantly associated with normalized brain volumes (p≤0.013), T2-LV, and T1-LV (p≤0.009). Hierarchical regression models selected EDSS as predictor of T25FW (adjusted-R2=0.186) and 9-HPT with the additional contribution of sex, normalized grey matter volume, and PASAT 2” (adjusted-R2=0.352).
In RRMS patients, motor and cognitive performances are related beyond the effect of structural disease-related burden, supporting the integration of motor and cognitive assessment in clinical settings.
Authors/Disclosures
Laura Cacciaguerra, MD, PhD (Mayo Clinic)
PRESENTER 		Dr. Cacciaguerra has nothing to disclose.
Damiano Mistri, MSC (Università Vita-Salute San Raffaele) Mr. Mistri has nothing to disclose.
Loredana Storelli Loredana Storelli has nothing to disclose.
Alessandro Meani Alessandro Meani has nothing to disclose.
Claudio Cordani Claudio Cordani has nothing to disclose.
Maria A. Rocca (Neuroimaging Research Unit) Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.